NICE TA671 - Mepolizumab for treating severe
eosinophilic asthma. As per NHSE commissioning intentions (Replaces NICE TA431)
DNP:
NICE TA845 - treating eosinophilic granulomatosis with polyangiitis. Terminated appraisal. (Decision date - December 2022)
NICE TA846 - treating severe hypereosinophilic syndrome. Terminated appraisal. (Decision date - December 2022)
NICE TA847 - treating severe chronic rhinosinusitis with nasal polyps. Terminated appraisal. (Decision date - December 2022)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
